1. Age The incidence of endometriosis malignancy increases with age. Meanwhile, in a study of 11 cases of endometriosis malignant transformation into endometrioid ovarian cancer, it was found that 8 cases occurred after menopause. This also indicates that endometriosis malignancy occurs more often in women of menopausal age. Therefore, postmenopausal endometriosis should be taken seriously by clinicians. If abdominal pain and distension are abnormal after menopause, or if the existing ovarian endohetero masses do not shrink significantly one year after menopause, or if the masses persist after menopause, or if new ovarian endohetero masses are found after menopause, endohetero malignant changes should be alerted. Varma et al. found that the probability of ovarian endometriosis developing into ovarian cancer was about 0.7%-1.6% through long-term follow-up, and the average year of malignancy was more than 8 years. It has also been shown that the younger the age of ovarian endometriosis, the higher the incidence of long-term malignancy. High levels of estrogen, especially with obesity, are currently recognized as risk factors for endometriosis malignancy. Therefore, estrogen therapy without progesterone resistance may play a role in ectopic endometriosis malignancy, and the simple application of estrogen therapy in obese or postmenopausal endometriosis patients increases the risk of malignancy. 4. Danazol Danazol is a classical drug for the treatment of endometriosis, however, studies have shown that it may have a correlation with ovarian cancer. cottreau et al. reported that the application of danazol for endometriosis could increase the risk of developing ovarian cancer by 3.2 times, while the application of leuprolide or nafarin treatment did not increase the risk of endometriosis malignancy. The main reason is that the application of danazol can increase the level of androgens, and androgen excess is closely related to the occurrence and development of ovarian cancer. 5. Menstruation and maternal history Early menarche, short cycle, late menopause and lower number of pregnancies and deliveries increase the chance of contaminating the pelvis during menstruation, which not only increases the incidence of endometriosis, but also its malignant rate. Studies have shown that the incidence of concomitant endometriosis in infertile ovarian cancer patients is twice as high as that in fertile patients, 22.9% and 12.6%, respectively. It has been reported that oral contraceptives and pregnancy can reduce estrogen levels, reduce the number of menstrual periods and menstrual volume, thus reducing the incidence of endometriosis and its malignant changes. 6.Environmental factors Dioxin is a major environmental pollutant with carcinogenic and teratogenic toxicity, and animal experiments have confirmed that dioxin can promote the occurrence, development and malignant transformation of endometriosis.